Outcome of Isolated Limb Infusion (ILI) Treatment for Chinese Acral Melanoma Patients With/without Gene Mutations.

Zhihong Chi,Li,Si Ming Li,Lu Si,Xi Nan Sheng,Chuan Liang Cui,Yan Kong,Jie Dai,Xuan Wang,Bi Xia Tang,Jun Guo

DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.e20014

IF: 45.3

2014-01-01

Journal of Clinical Oncology

Abstract:e20014 Background: Chinese melanoma patients had high incidence of limb in-transit metastasis because acral melanoma accounts for about 50% of melanoma in China. So far, isolated limb infusion (ILI) with melphalan and dactinomycin was used to treat patients with in-transit metastases in extremity. While many new targeted drugs were proved to be very effective to selected patients, for those patients with gene mutation, whether they can benefit from ILI or not is really confusing. Methods: Eighty-five stage III or IV acral melanoma patients with limb in-transit metastasis have been treated with isolated limb infusion from July 2009 to August 2013 in Peking University Cancer Hospital. ILI was performed using melphalan and dactinomycin (7.5mg/L and 75ug/L, respectively). Fifty-one of them had available gene mutation test results(C-KIT, BRAF, PDGFRA, NRAS). Objective response rate(ORR) and progression-free survival (PFS) was observed. Results: Of all the 51 patients. the mean age was 52 years old (24-79yr).Thirty-eight patients were male, 13 were female; 35 patients had stage III disease and 16 were stage IV. Fifteen (15/51, 29%) patients had gene mutation detected, including 9(18%) c-kit mutations, 3(6%) BRAF mutations, 3(6%) PDGFRA mutations, and 3(6%) NRAS mutations. Among which 4 patients had multiple gene mutations. In the gene mutation negative cohort, 17 (47%) of them achieved partial response and 16 (46%) had a stable disease, while in gene mutation positive cohort, 5 (33%) of them achieved partial response and 9(60%) had stable disease, no statistical significance were detected (P=0.7). The median PFS in the gene mutation positive cohort was 3 months (1-17m), while in the gene mutation negative cohort was 3 months (1-38m) as well. Conclusions: The outcome of isolated limb infusion treatment for Chinese acral melanoma patients seems worse than the result of the Caucasian, regardless of the status of gene mutation. Gene mutations don’t seem to affect the response of ILI-treated patients, for which gene mutation guided targeted therapy should be considered. Larger sample prospective trial is needed to confirm this result.